Gilead Sciences' Innovative Approach To An HIV Clinical Trial

When Gilead launched its Phase 3 study of investigational lenacapavir for PrEP, the team recognized that any clinical pathways intent on introducing...

Related Keywords

Rwanda ,South Africa ,United States ,Uganda ,Kigali ,W09 ,Ugandan ,South African ,Americans ,Moupali Das ,First Communications ,Gilead Sciences ,Us Centers For Disease ,Prep Clinical Program ,Global Community Accountability Group ,Community Engagement And Inclusion ,Program Lead ,Disease Control ,Saharan Africa ,Community Accountability Group ,Pre Exposure Prophylaxis ,Care System ,Prevention Not Reaching Enough Americans ,Patient Focused Selection ,Infect Dis Therapy ,Global Burden ,Disease Study ,